Presented by Policy Reporter, a TrialCard company

Gain critical insights into the dynamics of the oncology market to help drive your biosimilar strategy. In this white paper, we apply a synthesis of proprietary and public data to analyze the oncology market, applying lessons learned from the launch of Infliximab and more.

Our analysis discovered that health plans have adopted biosimilars of Trastuzumab as preferred products much sooner than was the case in the market of  Infliximab and more. Download this white paper to learn more about oncology market drivers and behaviors.